Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024
Standard BioTools Inc. (NASDAQ: LAB) has announced its plans to report third quarter 2024 financial results on Wednesday, October 30, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET on the same day to discuss the results and operational progress.
Interested individuals can join the call by dialing (888) 346-3970 for US domestic callers or (412) 902-4297 for international callers. A live audio webcast will be available on the company's Investor Relations page. The webcast will be archived for future access on Standard BioTools' Investor Relations page at investors.standardbio.com.
Standard BioTools Inc. (NASDAQ: LAB) ha annunciato i suoi piani per riportare i risultati finanziari del terzo trimestre 2024 mercoledì 30 ottobre 2024, dopo la chiusura del mercato. L'azienda ospiterà una teleconferenza e webcast alle 13:30 PT, 16:30 ET nello stesso giorno per discutere i risultati e i progressi operativi.
Le persone interessate possono partecipare alla chiamata componendo il numero (888) 346-3970 per i chiamanti domestici degli Stati Uniti o (412) 902-4297 per i chiamanti internazionali. Un webcast audio in diretta sarà disponibile sulla pagina delle Relazioni con gli Investitori dell'azienda. Il webcast sarà archiviato per un accesso futuro sulla pagina delle Relazioni con gli Investitori di Standard BioTools all'indirizzo investors.standardbio.com.
Standard BioTools Inc. (NASDAQ: LAB) ha anunciado sus planes para informar los resultados financieros del tercer trimestre de 2024 el miércoles 30 de octubre de 2024, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia y webcast a la 1:30 p.m. PT, 4:30 p.m. ET el mismo día para discutir los resultados y el progreso operativo.
Las personas interesadas pueden unirse a la llamada marcando (888) 346-3970 para los llamadores nacionales de EE. UU. o (412) 902-4297 para los llamadores internacionales. Se dispondrá de una transmisión web de audio en vivo en la página de Relaciones con los Inversores de la empresa. La transmisión se archivará para acceso futuro en la página de Relaciones con los Inversores de Standard BioTools en investors.standardbio.com.
Standard BioTools Inc. (NASDAQ: LAB)는 2024년 10월 30일 수요일 장 마감 후 2024년 3분기 재무 결과를 발표할 계획을 발표했습니다. 같은 날 오후 1시 30분 PT, 오후 4시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 개최하여 결과와 운영 진행 상황에 대해 논의할 예정입니다.
관심 있는 분들은 미국 내 전화 거는 분은 (888) 346-3970 또는 국제 전화 거는 분은 (412) 902-4297로 전화를 걸어 참가할 수 있습니다. 회사의 투자자 관계 페이지에서 실시간 오디오 웹캐스트가 제공됩니다. 웹캐스트는 나중에 Standard BioTools의 투자자 관계 페이지에서 접근할 수 있도록 아카이브됩니다. (investors.standardbio.com).
Standard BioTools Inc. (NASDAQ: LAB) a annoncé ses plans pour publier les résultats financiers du troisième trimestre 2024 le mercredi 30 octobre 2024, après la fermeture du marché. L'entreprise organisera un appel conférence et un webinaire le même jour à 13h30 PT, 16h30 ET pour discuter des résultats et des avancées opérationnelles.
Les personnes intéressées peuvent participer à l'appel en composant le (888) 346-3970 pour les appelants nationaux aux États-Unis ou le (412) 902-4297 pour les appelants internationaux. Un webinaire audio en direct sera disponible sur la page des Relations Investisseurs de l'entreprise. Le webinaire sera archivé pour un accès futur sur la page des Relations Investisseurs de Standard BioTools à l'adresse investors.standardbio.com.
Standard BioTools Inc. (NASDAQ: LAB) hat seine Pläne zur Veröffentlichung der Finanzergebnisse des dritten Quartals 2024 für Mittwoch, den 30. Oktober 2024, nach Börsenschluss angekündigt. Das Unternehmen wird am selben Tag um 13:30 Uhr PT, 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse und den operativen Fortschritt zu besprechen.
Interessierte Personen können sich an der Konferenz beteiligen, indem sie (888) 346-3970 für Anrufer aus den USA oder (412) 902-4297 für internationale Anrufer wählen. Ein Live-Audio-Webcast wird auf der Investor-Relations-Seite des Unternehmens verfügbar sein. Der Webcast wird für den zukünftigen Zugriff auf der Investor-Relations-Seite von Standard BioTools unter investors.standardbio.com archiviert.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market.
The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
Gilmartin Group LLC
ir@standardbio.com
FAQ
When will Standard BioTools (LAB) report its Q3 2024 financial results?
What time is Standard BioTools' (LAB) Q3 2024 earnings call scheduled for?
How can investors access Standard BioTools' (LAB) Q3 2024 earnings call?
Where can I find the archived webcast of Standard BioTools' (LAB) Q3 2024 earnings call?
